BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitorsGarrett W. Rhyasen(AstraZeneca (United States)), Huawei Chen(AstraZeneca (Brazil))PLoS ONEJuly 23, 201810.1371/journal.pone.0200826Cited by 54SaveCiteExport RISWatch citationsRelated PapersPharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer|Cancer Research|2018|45